Median Technologies partners with Canon’s Olea Medical to commercialize eyonis LCS lung cancer screening software

Reuters2026/07/30 15:52

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Median Technologies signed a global commercialization agreement with Olea Medical, a Canon Medical Systems unit, for its eyonis LCS lung cancer screening AI software.
Olea will co-market the product in the US and Europe, leveraging Canon’s installed base in CT imaging used for lung screening.
The deal targets commercial rollout following FDA 510(k) clearance in February 2026 and CE marking in July 2026.
Median is pursuing a multi-channel go-to-market model combining direct sales with non-exclusive distribution partnerships, including an earlier tie-up with Tempus AI.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Median Technologies SA published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Median Technologies partners with Canon’s Olea Medical to commercialize eyonis LCS lung cancer screening software

You may also like

Crypto prices